Edition:
Deutschland

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

60.17USD
16 Feb 2018
Change (% chg)

$0.67 (+1.13%)
Prev Close
$59.50
Open
$59.46
Day's High
$60.53
Day's Low
$59.34
Volume
2,009,006
Avg. Vol
1,769,791
52-wk High
$64.60
52-wk Low
$42.32

ABT.N

Chart for ABT.N

About

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded... (more)

Buy/Sell

Sell Hold Buy
1.80 Mean rating from 20 analysts

Overall

Beta: 1.57
Market Cap(Mil.): $95,559.38
Shares Outstanding(Mil.): 1,737.44
Dividend: 0.26
Yield (%): 1.93

BRIEF-Agios says FDA Accepts NDA And Grants Priority Review For Ivosidenib

* FDA ACCEPTS NEW DRUG APPLICATION AND GRANTS PRIORITY REVIEW FOR IVOSIDENIB IN RELAPSED OR REFRACTORY AML WITH AN IDH1 MUTATION

India cuts stent prices by more than 7 percent

NEW DELHI, Feb 12 India has cut prices of some stents by about 7.6 percent, a government body said on Monday, in the latest setback for the country's $5 billion medical device industry.

Photo

Exclusive - J&J out of race for Pfizer's $20 billion consumer unit as deadline looms

LONDON/NEW YORK/FRANKFURT Johnson & Johnson has pulled out of the race to buy Pfizer's consumer health business, leaving GlaxoSmithKline and Reckitt Benckiser among those preparing bids, according to sources familiar with the matter.

Photo

Exclusive: J&J out of race for Pfizer's $20 billion consumer unit as deadline looms

LONDON/NEW YORK/FRANKFURT Johnson & Johnson has pulled out of the race to buy Pfizer's consumer health business, leaving GlaxoSmithKline and Reckitt Benckiser among those preparing bids, according to sources familiar with the matter.

EXCLUSIVE-J&J out of race for Pfizer's $20 bln consumer unit as deadline looms

LONDON/NEW YORK/FRANKFURT, Jan 25 Johnson & Johnson has pulled out of the race to buy Pfizer's consumer health business, leaving GlaxoSmithKline and Reckitt Benckiser among those preparing bids, according to sources familiar with the matter.

US STOCKS-S&P 500 dips after choppy session; chipmakers drag Nasdaq

* Dow up 0.16 pct, S&P 500 down 0.06 pct, Nasdaq down 0.61 pct

Deals of the day-Mergers and acquisitions

Jan 24 The following bids, mergers, acquisitions and disposals were reported by 2030 GMT on Wednesday:

US STOCKS-Wall St Flat in choppy session, Nasdaq lags

NEW YORK, Jan 24 Both the Dow and S&P 500 edged higher on Wednesday while the Nasdaq lost ground in choppy trading in the wake of comments by U.S. Commerce Secretary Wilbur Ross which hinted at action against China in a trade war.

REFILE-US STOCKS-Wall St heads lower after Wilbur Ross comments on China

Jan 24 U.S. stocks fell on Wednesday after Commerce Secretary Wilbur Ross called China's 2025 technology strategy a "direct threat" and hinted at action against Beijing, stirring fears of a tit-for-tat trade war.

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.24%
Rohstoffe -0.32%
Industrie -0.21%
Konjunktur abhängige Waren & Dienstleistungen -0.18%
Konjunktur unabhängige Waren & Dienstleistungen -0.16%
Finanzindustrie -0.08%
Pharma -0.07%
Technologie -0.19%
Telekommunikation -0.05%